Navigation Links
Histogen’s Composition for Hair Growth Receives US Patent

San Diego, CA (PRWEB) September 17, 2013

Histogen, Inc., a regenerative medicine company developing innovative therapies based on the products of cells grown under simulated embryonic conditions, today announced that the United States Patent & Trademark Office has issued patent 8,535,913, entitled “Soluble Composition for Promoting Hair Growth Produced by Hypoxic Culture of Fibroblast Cells”.

The patent, which is the fourth US patent issued to the Company, covers the liquid composition of proteins and cofactors that is secreted by multipotent stem cells through Histogen’s technology process, and the method of administering that composition to stimulate hair growth. Histogen’s Hair Stimulating Complex (HSC), covered by this new patent, is in clinical development as an injectable treatment for male pattern and female diffuse hair loss.

“We are extremely pleased that HSC, and future hair restoration treatments using this technology, are now bolstered by a US patent,” said Dr. Gail K. Naughton, Histogen CEO and Chairman of the Board. “At a time when the industry continues to uncover information about how cell-signaling results in hair growth and maintenance, patent protection for our unique composition of proteins and growth factors is of great benefit to Histogen and its future partners.”

Several factors critical to hair growth such as follistatin, VEGF and KGF, are present in HSC, and their secretion by the cells is stimulated by low oxygen and special culture conditions utilized by Histogen. The conditions under which the cells are manufactured not only upregulates genes associated with hair growth, but induces significantly increased production of these critical factors than seen with traditional culture conditions.

In two Company-sponsored clinical trials, HSC has resulted in statistically significant increases across hair growth parameters, including hair count, density and thickness. In addition, the treatment has shown efficacy in difficult-to-treat patient groups, including women, older subjects and those with temporal recession region hair loss. Histogen looks forward to progressing HSC to the next clinical stage, and to further analyzing its newly-patented composition.

About Histogen
Histogen is a regenerative medicine company developing solutions based upon the products of cells grown under proprietary conditions that mimic the embryonic environment, including low oxygen and suspension. Through this unique technology process, newborn cells are encouraged to naturally produce the vital proteins and growth factors from which the Company has developed its rich product portfolio. Histogen’s technology focuses on stimulating a patient’s own stem cells by delivering a proprietary complex of multipotent human proteins that have been shown to support stem cell growth and differentiation. For more information, please visit

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Histogen’s Method of Generating Multipotent Stem Cells Receives US Patent
2. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
3. Bio/Pharmaceutical Contract Manufacturing - Industry Analysis of Dose Manufacturing by the Numbers: Composition, Size, Market Shares, Profitability and Outlook
4. Downsizing and the Need for Increased Selling Effectiveness Fuel Delta Points Growth
5. RSB Spine, LLC Announces 2011 Revenue Growth
6. ERT Launches New Website to Support Significant Commercial Growth
7. Phalanx Biotech Group Reports Robust Revenue Growth in 2011
8. Synthetic Biologics to Present at ROTH Annual Growth Stock Conference
9. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
10. Carbon nanotubes can double growth of cell cultures important in industry
11. CannaBANK Acquires Rights to License PharmaSpheres Patented Growth System
Post Your Comments:
(Date:10/13/2015)... Florida , October 13, 2015 ... specializing in the development of innovative peptide and gene-based ... metastatic disease, will be a featured presenting company at ... at the Wyndham Grand Hotel in Jupiter, ... TapImmune, Inc. (TPIV), a clinical-stage immunotherapy company ...
(Date:10/13/2015)... ... 2015 , ... Clinovo recently appointed Jeff Parr and Ed Donaldson to its ... solutions business. , Jeff Parr has spent the past decade providing quality management software ... Fisher, and Ab Sciex to name a few. He is based in Salt ...
(Date:10/13/2015)... -- the United States , ... about 14% of all new cases of kidney cancer.   ... and Europe .  PRCC represents about ... Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that ... (publ) ("AstraZeneca") have completed enrolment in a global Phase II study ...
(Date:10/12/2015)... , Oct. 12, 2015 This report covers ... include cell type, products, applications, end-user markets and geographic ... HIGHLIGHTS The global cell expansion market generated revenue ... to reach revenues of $9.7 billion in 2015 and ... rate (CAGR) of 17.8% from 2015 to 2020. ...
Breaking Biology Technology:
(Date:10/6/2015)... Oct. 6, 2015 Track Group, Inc. (OTCQX: ... it has signed a contract with the Virginia Department ... full range of sentences under the Department,s oversight. ... Americas. "This contract with the Virginia DOC will expand ... and advances our position as a trusted leader in ...
(Date:9/30/2015)... , Sept. 30, 2015  With nearly 300,000 ... number of new SCIs estimated to reach 12,500 annually, ... Southern California Resource Services for Independent Living (SCRS-IL) ... in California opening doors to ... of programs and services, notably assistive technology services and ...
(Date:9/28/2015)... YORK , Sept. 28, 2015 /PRNewswire/ ... announced today that its expedited traveler service ... innovative platform transforms travel, bringing a frictionless ... its members. "CLEAR offers our ... enhances customer service," said Jim Smith ...
Breaking Biology News(10 mins):